|
OPEN
PROTOCOLS- September 2004
|
BREAST
|
|
|
Study
No. |
Study
Title
|
|
|
Aventis
XRP9881B/3001
|
A
Randomized, Open-Label, Phase III Study of RPR109881 IV Every
3 Weeks Versus Capecitabine (Xeloda®) Tablets Twice Daily
For 2 Weeks in 3-Week Cycles In Patients With Metastatic Breast
Cancer Progressing After Taxane/Anthracycline Therapy
|
|
|
|
Genentech
H2757n
HER-2 Registry
|
AN
OBSERVATIONAL COHORT STUDY OF PATIENTS WITH
HER2-POSITIVE METASTATIC BREAST CANCER
|
|
|
GASTROINTESTINAL
|
|
|
Study
No. |
Study
Title
|
|
|
Pfizer/
Pharmacia CPTAIV-0020-411 |
A
Randomized, Multicenter, Phase III, Trial of Irinotecan in
Combination with 3 Different Ways of Administering Fluoropyrimidine:
Infusional 5-FU, Bolus 5-FU (Day 1&8) and Oral Capcitabine
(Day1-14);with Celecoxib vs Placebo as First Line Treatment
of Patients with Metastatic Colorectal Cancer; AVASTIN ALLOWED.
|
|
|
|
Novartis
CPTL787 0133 |
Phase
III, Randomized, Double-Blind, Placebo-controlled, study of
Oxaliplatin-5-FU/LV with or without PTK787/ZK 222584 for the
Treatment of Patients with Metastatic Adenocarcinoma of
the Colon or Rectum Whose Disease has Recurred or Progressed
Following Treatment with Irinotecan in Combination with a
Fluoropyrimidine (No prior OXALIPLATIN)
|
|
|
|
AMGEN
ABX-EGF
20030167 |
A
Phase II Multicenter Single Arm Trial of ABX-EGF (Panitumumab)
Monotherapy in Patients with Metastatic CRC Following Treatment
with 5FU, Irinotecan, and Oxaliplatin Therapy.
|
|
|
HEMATOLOGIC
/ LYMPHOMAS
|
|
|
Study
No. |
Study
Title
|
|
|
Salmedix
105-02 |
A
Multi-Center Phase II Study To Investigate The Safety And
Activity Of SDX-105 (Bendamustine) In Combination With Rituximab
In Patients With Relapsed Indolent Or Mantle Cell Non-Hodgkin's
Lymphoma (NHL)
|
|
|
|
Genentech
U2963n |
The
National Lymphocare Study: An Observational Study Of Treatment,
Outcomes And Prognosis In Patients with Follicular Nnon-Hodgkin's
Lymphoma |
|
|
GENITOURINARY
/ GYN
|
|
|
Study
No. |
Study
Title
|
|
|
Telik
TLK 286 |
Phase
3, Randomized Study of TLK286 (Telcyta) Versus Doxil or Hycamtin
as Thrid-Line Therapy in Platinum Refractory or Resistant
Ovarian Cancer. (Must have had 2nd line Doxil or Hycamtin)
|
|
|
LUNG
|
|
|
Study
No. |
Study
Title
|
|
|
Dartmouth
D-0112 |
A
Multicenter, Randomized Phase III Study Of Taxotere And Carboplatin
Versus Taxotere And Gemcitabine In Patients With Advanced
Non-Small Cell Lung Cancer (1st line)
|
|
|
SUPPORTIVE
/ MISC.
|
|
|
Study
No. |
Study
Title
|
|
|
Amgen
20030218 (FIRST) |
A
Multicenter, Open-Label, Phase 4 Study of Pegfilgrastim Administered
in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
|
|
|
|
